Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hyperkalemia. Objectives Definition Brief review of potassium regulation processes Causes Clinical Manifestations Therapy Proposals for standardized management.

Similar presentations


Presentation on theme: "Hyperkalemia. Objectives Definition Brief review of potassium regulation processes Causes Clinical Manifestations Therapy Proposals for standardized management."— Presentation transcript:

1 Hyperkalemia

2 Objectives Definition Brief review of potassium regulation processes Causes Clinical Manifestations Therapy Proposals for standardized management

3 Definition Hyperkalemia = plasma K+ concentration > 5.0mmol/L Critical hyperkalemia = plama K+ concentration > 6.5 mmol/L UNM Lab Ranges: Normal 3.5-5.1 Critical 6.5 for women, 7 for men

4 Potassium Regulation Review Intracellular concentration about 150 mmol/L The passive outward diffusion of K+ is the most important factor that generates the resting membrane potential. Maintenance of steady state requires K+ ingestion = K+ excretion Nearly all regulation of renal K+ excretion and total body K+ balance occurs in the distal nephron, via principal cells Potassium secretion regulated by aldosterone and plasma K+ concentration

5 Causes of Hyperkalemia I.Potassium release from cells II.Decreased renal loss III.Iatrogenic (Consider pseudohyperkalemia)

6 Potassium release from cells Intravascular hemolysis Tumor Lysis Syndrome Rhabdomyolysis Non-gap metabolic acidosis Hyperglycemia Severe Digitalis toxicity Hyperkalemic periodic paralysis Beta-blockers Succinylcholine; especially in case massive trauma, burns or neuromuscular disease

7 Decreased renal loss Renal failure Decreased distal flow Decreased K+ secretion Impaired Na+ reabsorption adrenal insufficiency adrenal enzyme deficiency hyporeninemic hypoaldosteronism drugs: ACEi, NSAIDS, heparin, K+-sparing diuretics, trimethoprim, pentamidine tubulointerstitial disease distal type 4 RTA Enhanced Cl- reabsorption Cyclosporine Gordon’s syndrome

8 Clinical Manifestations Weakness, which can progress to flaccid paralysis and hypoventilation. Secondary to prolonged partial depolarization from the elevated K+, which impairs membrane excitability. Metabolic acidosis, which further increases K+ Secondary to hyperkalemia impairing renal ammoniagenesis and absorption, and thus net acid excretion. Altered electrical activity of heart, cardiac arrhythmias. ECG changes in order of appearance: Tall, narrow-based, peaked T waves Prolonged PR interval and QRS duration AV conduction delay Loss of P waves Progression of QRS duration leading to sine wave pattern Ventricular fibrillation or asystole

9 Therapy 1.Determine needed approach – if emergent or not. Typically, potential fatal hyperkalemia occurs with K+ > 7.5 and associated with profound weakness. THIS CANNOT BE COUNTED ON; cardiac toxicity does not correlate well with plasma K+ concentration. MUST OBTAIN STAT ECG. 2.Determine underlying cause(s) once patient treated to maintain stability If K+ high and ECG normal, consider pseudohyperkalemia Usually, chronic hyperkalemia is due to impaired K+ excretion Review medications, oral and all IV therapies Evaluate effective circulating volume Patients with Kidney disease are highest risk of developing hyperkalemia. Consider the combination of: HCO3 105, Cr > 1.5, diabetic as high risk for hyperkalemia.

10 Emergent Therapy 1.10 ml of a 10% solution calcium gluconate infused over 2-3 minutes. onset of action several minutes, lasts 30 – 60 minutes 2.10-20 units regular insulin with 25-50 g glucose IV onset action 15-30 minutes, lasts several hours. K+ drops 0.5-1.5 mmol/L. no glucose if patient hyperglycemic 3.Nebulized or parental Beta-agonist onset action 30 minutes, lasts 2-4 hours. K+ drops 0.5 to 1.5 mmol/L. 4.IV NaHCO3 as isotonic solution of 3 amps per liter 5% dextrose Ideally reserved for severe hyperkalemia associated with metabolic acidosis avoid in patients with ESRD; not tolerated and they seldom respond. Little medical evidence for use. 5. Loop and thiazide diuretics if renal function adequate and not dehydrated 6.Cation exchange resin, ie Kayexalate. 25-50 g mixed with 100 ml 20% sorbitol orally, or 30-60 min retention enema with 50 g resin in 150 ml H20. onset 1-2 hours and lasts 4-6 hours. K+ drops 0.5-1.5 mmol/L 7.Dialysis Peritoneal is only 15% as effective as hemodialysis

11

12

13 Proposals for standardized management 1.No treatment, other than kayexalate, for K 5.1 – 6 unless medical condition strongly predicts the value will continue to increase. Examples: acute oliguric renal failure, tumor lysis syndrome. Do repeat and f/u on potassium level. 2.Policy that for any K+ > 6.0, order ECG. Consider stat repeat K+ if concern pseudohyperkalemia 3.For persistent K+ > 5.1, order telemetry 4.Policy if K+ <6.5 and no ECG changes present, treat with kayexalate and repeat K+ level and ECG in 4-6 hours. No need other interventions. 5.Policy if K+ < 6.5 and ECG changes present, administer CaGluconate, Insulin/Glucose, Nebulizer Rx, and Kayexalate. Consider consult ICU team. 6.Policy if K+ > 6.4, regardless of presence of ECG changes, administer CaGluc, Insulin/Glucose, Nebulizer Rx, and Kayexalate. Repeat ECG and K+ level in 1 hour. Consider consult ICU team.

14 References 1.Harrisons Principles of Internal Medicine. 17 th Edition. 2008. 2.Alfonzo, Annette V.M. Review paper: Potassium disorders-clinical spectrum and emergency management. Resuscitation (2006) 70, 10 -25. 3.Sood, Manish M. Emergency Management and Commonly Encountered Outpatient Scenarios in Patients With Hyperkalemia. Mayo Clinic Proc. 2007; 82(12): 1553- 1561. 4.Tzamaloukas, A. Pathophysiology and Management of Fluid and Electrolyte Disturbances in Patients on Chronic Dialysis with Severe Hyperglycemia. Seminars in Dialysis. 2008; 21(5): 431-439.


Download ppt "Hyperkalemia. Objectives Definition Brief review of potassium regulation processes Causes Clinical Manifestations Therapy Proposals for standardized management."

Similar presentations


Ads by Google